Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment

References

• Norway CRo. Cancer in Norway 2020 - Cancer incidence, mortality, survival and prevalence in Norway [Internet]. Oslo: Cancer Registry of Norway; 2021. [cited 2021]. Available from: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2020/cin-2020.pdf.
   Google Scholar
• Witjes Hmb JA, Cathomas R, Compérat E, et al. The EAU guidelines on muscle-invasive and metastatic bladder cancer 2021. [cited 2021 Jun 6]. Available from: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
   Google Scholar
• Westergren DO, Gårdmark T, Lindhagen L, et al. A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014. J Urol. 2019;202(5):905–912.
   PubMed Web of Science ®Google Scholar
• Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølgning av blaerekreft Oslo: Helsedirektoratet; 2013. [cited 2021 Aug 3]. Available from: https://blaerekreft.no/wp-content/uploads/Nasjonalt-handlingsprogram-bl%C3%A6rekreft.pdf.
   Google Scholar
• Yiou R, Patard JJ, Benhard H, et al. Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int. 2002;89(4):374–378.
   PubMed Web of Science ®Google Scholar
• Schrier BP, Hollander MP, van Rhijn BW, et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004 Mar;45(3):292–296.
   PubMed Web of Science ®Google Scholar
• May M, Helke C, Nitzke T, et al. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int. 2004;72(2):103–111.
   PubMed Web of Science ®Google Scholar
• Ferreira U, Matheus WE, Nardi Pedro R, et al. Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate. Urol Int. 2007;79(3):200–203.
   PubMed Web of Science ®Google Scholar
• Lee CT, Dunn RL, Ingold C, et al. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology. 2007;69(6):1068–1072.
   PubMed Web of Science ®Google Scholar
• de Vries RR, Nieuwenhuijzen JA, Vincent A, et al. Survival after cystectomy for invasive bladder cancer. Eur J Surg Oncol. 2010 Mar;36(3):292–297.
   PubMed Web of Science ®Google Scholar
• Kotb AF, Kovac E, Kassouf W, et al. Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? World J Urol. 2012;30(6):761–767.
   PubMed Web of Science ®Google Scholar
• Aziz A, Gierth M, Fritsche HM, et al. Oncological outcome of primary versus secondary Muscle-Invasive bladder cancer is comparable after radical cystectomy. Urol Int. 2013;91(1):97–102.
   PubMed Web of Science ®Google Scholar
• Hidas G, Pode D, Shapiro A, et al. The natural history of secondary muscle-invasive bladder cancer. BMC Urol. 2013;13:23.
   PubMed Web of Science ®Google Scholar
• Breau RH, Karnes RJ, Farmer SA, et al. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int. 2014;113(6):900–906.
   PubMed Web of Science ®Google Scholar
• May M, Burger M, Brookman-May S, et al. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer. Clin Genitourin Cancer. 2014;12(4):278–286.
   PubMed Web of Science ®Google Scholar
• Moschini M, Sharma V, Dell’oglio P, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117(4):604–610.
   PubMed Web of Science ®Google Scholar
• Zakaria AS, Santos F, Kassouf W, et al. Survival after radical cystectomy for bladder cancer in relation to prior non-muscle invasive disease in Quebec. Urol Int. 2016;97(1):49–53.
   PubMed Web of Science ®Google Scholar
• Lusty A, Doiron RC, Booth CM, et al. No outcome differences after cystectomy between patients with De novo Muscle-Invasive bladder cancer compared to progressors: a retrospective population-based study. J Urol. 2021;206(2):260–269.
   PubMed Web of Science ®Google Scholar
• Blindheim A, Fosså S, Babigumira R, et al. T1 bladder cancer in Norway: treatment and survival. Scand J Urol. 2020;54(5):370–375.
   PubMed Web of Science ®Google Scholar
• International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th ed. Sobin L, Wittekind C, editors. New York: Wiley; 2002.
   Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–290.
   Web of Science ®Google Scholar
• Chen J, Zhang H, Sun G, et al. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: a systematic review and meta-analysis. Int J Surg. 2018;52:214–220.
   PubMed Web of Science ®Google Scholar
• Pones M, D’Andrea D, Mori K, et al. Differential prognosis and response of denovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis. Cancers (Basel). 2021;13(10):2496.
   PubMed Web of Science ®Google Scholar
• Ge P, Wang L, Lu M, et al. Oncological outcome of primary and secondary muscle-Invasive bladder cancer: a systematic review and meta-analysis. Sci Rep. 2018;8(1):7543.
   PubMed Web of Science ®Google Scholar
• Zheng XN, Qiu S, Yang L, et al. Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: an updated meta-analysis. Int J Med Sci. 2021;18(2):505–510.
   PubMed Web of Science ®Google Scholar
• Russell B, Liedberg F, Khan MS, et al. A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol. 2020;3(2):239–249.
   PubMed Web of Science ®Google Scholar
• Pietzak EJ, Zabor EC, Bagrodia A, et al. Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur Urol. 2019;75(2):231–239.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4(10):1140–1153.
   PubMed Web of Science ®Google Scholar
• El-Abbady AA, Shoukry MS, Hanno AG, et al. Repeated transurethral resection of recurrent superficial bladder tumors-does it affect the spread and stage of the tumor? Scand J Urol Nephrol. 2002;36(1):60–64.
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Ost P, Bellmunt J, et al. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review. Eur Urol. 2018;73(1):40–50.
   PubMed Web of Science ®Google Scholar